A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
The LUMA trial (NCT05348785) represents one of the most advanced clinical programs for a disease-modifying therapy in Parkinson's disease. BIIB122 (formerly DNL151) is a potent, selective, oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) developed by Biogen in collaboration with Denali Therapeutics. The trial is specifically designed to evaluate whether inhibiting LRRK2 kinase activity can slow the progression of early-stage Parkinson's disease[1].
Parkinson's disease affects approximately 10 million people worldwide, representing one of the most significant unmet medical needs in modern medicine. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options. Current treatments provide symptomatic relief but do not address the underlying neurodegenerative process[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT05348785 |
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Biogen |
| Enrollment | 650 participants |
| Enrollment Type | ACTUAL |
| Study Type | INTERVENTIONAL |
| Start Date | 2022-04-19 00:00:00 |
| Completion Date | 2026-03-09 00:00:00 |
| Last Updated | 2025-10-23 00:00:00 |
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability, as well as non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction[2:1].
Pathologically, PD is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, which are intracellular inclusions composed primarily of alpha-synuclein protein. Current treatments provide symptomatic relief but do not halt disease progression.
LRRK2 (Leucine-Rich Repeat Kinase 2) is a large multi-domain protein with intrinsic kinase activity. Pathogenic variants in the LRRK2 gene, particularly the G2019S variant, are among the most common genetic causes of familial PD and also contribute to sporadic disease risk.
The LRRK2 protein consists of multiple functional domains:
All pathogenic LRRK2 mutations increase kinase activity by two- to threefold, leading to hyperphosphorylation of downstream substrates[3].
LRRK2 hyperactivity leads to:
Impaired autophagy-lysosomal pathway function: LRRK2 phosphorylates Rab GTPases (including Rab8A, Rab10, Rab12, Rab29, and Rab35) at their Switch II region. Phosphorylated Rabs lose affinity for their regulatory proteins, disrupting normal vesicular trafficking and lysosomal function.
Mitochondrial dysfunction: LRRK2 mutations impair mitochondrial dynamics and mitophagy, partly through interactions with the PINK1-Parkin pathway.
Synaptic alterations: LRRK2 affects synaptic vesicle trafficking and neurotransmitter release.
Increased neuronal vulnerability: The combined effects create a permissive environment for alpha-synuclein aggregation and dopaminergic neuron death.
BIIB122 is a potent, selective, small-molecule inhibitor of LRRK2 kinase activity. By inhibiting LRRK2, BIIB122:
The therapeutic rationale is straightforward: if excessive LRRK2 kinase activity drives neurodegeneration, then pharmacological kinase inhibition should slow or halt disease progression[4].
This is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial. Phase 2b trials build upon Phase 2a safety data to evaluate efficacy and identify optimal dosing regimens in larger populations[5].
Key features of the LUMA trial design include:
| Arm | Intervention | Dose | Route | Frequency |
|---|---|---|---|---|
| Experimental | BIIB122 | 225 mg | Oral (tablet) | Once daily |
| Placebo Comparator | BIIB122 Matching Placebo | N/A | Oral (tablet) | Once daily |
Key inclusion criteria for LUMA:
Key exclusion criteria:
Confirmed worsening is defined as:
The MDS-UPDRS is the gold-standard measure for PD severity:
A unique feature of LRRK2 inhibitor trials is the availability of robust pharmacodynamic biomarkers:
Phospho-Rab10 (pRab10): The gold-standard readout of LRRK2 kinase inhibition. BIIB122 treatment produces dose-dependent reductions in pRab10 in peripheral blood neutrophils[6].
Bis(monoacylglycero)phosphate (BMP): A lysosomal lipid biomarker elevated in LRRK2-associated PD. Reductions indicate improved lysosomal function.
These biomarkers allow direct measurement of target engagement in humans, greatly facilitating dose selection and proof-of-concept studies.
This clinical trial represents a critical step in the development of new treatments for Parkinson's disease[7]:
First large-scale LRRK2 inhibitor efficacy trial: LUMA is the largest and most advanced LRRK2 inhibitor trial to date, potentially providing the first definitive evidence for disease modification through LRRK2 inhibition
Genetic validation: LRRK2 is one of the most genetically validated drug targets in PD, with pathogenic mutations causing familial disease and contributing to sporadic risk
Disease modification: Unlike current treatments that only address symptoms, LRRK2 inhibition targets the underlying neurodegenerative process
Broad applicability: The trial enrolls both LRRK2-associated and idiopathic PD patients, testing the hypothesis that LRRK2 kinase activity is elevated even in sporadic disease
Regulatory path: Successful results would establish a clear regulatory pathway for LRRK2 inhibitors in PD
| Trial | Target | Phase | Status |
|---|---|---|---|
| LUMA (NCT05348785) | LRRK2 | Phase 2b | Active, results expected late 2025 |
| SPARK (NCT04777353) | Alpha-synuclein immunotherapy | Phase 2 | Recruiting |
| CYCLONE (NCT04710043) | Alpha-synuclein ASO | Phase 1/2 | Active |
| PASADENA | Alpha-synuclein vaccine | Phase 2 | Completed |
The LRRK2 inhibitor approach represents a fundamentally different mechanism than immunotherapy or gene therapy approaches, offering a small-molecule oral treatment option.
BIIB122 demonstrates favorable pharmacokinetic properties for CNS drug development:
Absorption:
Distribution:
Metabolism:
Elimination:
Target Engagement:
Biomarker Response:
Dose selection in LUMA was informed by:
The chosen 225 mg daily dose achieves:
The Movement Disorder Society Unified Parkinson's Disease Rating Scale is the gold standard for PD clinical trials:
Part I: Non-Motor Experiences of Daily Living (13 items, score 0-52)
Part II: Motor Experiences of Daily Living (13 items, score 0-52)
Part III: Motor Examination (33 items, score 0-132)
Part IV: Motor Complications (6 items, score 0-24)
Primary endpoint uses "confirmed worsening":
Assumptions:
Sample Size Calculation:
LRRK2 phosphorylates Rab GTPases that regulate vesicular trafficking:
LRRK2 kinase activation
↓
Rab8A, Rab10, Rab12, Rab29, Rab35 phosphorylation
↓
Dissociation from GDI/GDF proteins
↓
Impaired lysosomal trafficking
↓
Accumulation of autophagosomes
↓
α-Synuclein aggregation
↓
Neuronal death
Mutant LRRK2 impairs mitophagy:
LRRK2 is highly expressed in microglia:
BIIB122 administration
↓
LRRK2 kinase inhibition
↓
Reduced Rab phosphorylation
↓
Restored vesicular trafficking
↓
Enhanced lysosomal function
↓
Reduced α-synuclein aggregation
↓
Neuronal protection
↓
Slowed disease progression
The trial enrolls both populations:
| Characteristic | LRRK2-PD | Idiopathic PD |
|---|---|---|
| Prevalence | 5-10% | 90-95% |
| Age at onset | 50-60 years | 60-70 years |
| Disease progression | Similar | Similar |
| Response to levodopa | Similar | Similar |
Key Hypothesis: LRRK2 kinase activity is elevated in both groups, so inhibitor will benefit idiopathic PD as well.
Stage 1-2.5 selection rationale:
DaTscan (dopamine transporter imaging) confirms:
Assay:
Clinical Correlation:
Limitations:
Function:
Assay:
Biomarker Utility:
Function:
Utility in LUMA:
If LUMA meets primary endpoint:
| Program | Status | Lessons |
|---|---|---|
| DNL151 (Denali) | Phase 1/2 | Safety established |
| LGI-A (GSK) | Discontinued | AE profile |
| ASN003 (AbbVie) | Discontinued | Insufficient efficacy |
Key considerations:
| Approach | Target | Advantages | Limitations |
|---|---|---|---|
| LRRK2 inhibitor | LRRK2 | Oral, small molecule | Requires continued dosing |
| α-Synuclein antibody | Extracellular αSyn | Immunization | IV infusion |
| Gene therapy | GBA, others | One-time | Surgical |
| Cell therapy | Dopamine cells | Regeneration | Immunogenicity |
| Trial | LRRK2+ | Idiopathic | Total |
|---|---|---|---|
| LUMA | ~65 (10%) | ~585 | 650 |
| SPARK | 0 | 312 | 312 |
| PASADENA | 0 | 316 | 316 |
Potential future strategies:
Future trials may use:
Given strong genetic rationale: